Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI.

Eur Urol. 2018 Sep 1. pii: S0302-2838(18)30594-3. doi: 10.1016/j.eururo.2018.08.009. [Epub ahead of print]

PMID:
30181068
2.

Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA.

Mol Cancer Ther. 2018 Nov;17(11):2473-2480. doi: 10.1158/1535-7163.MCT-18-0174. Epub 2018 Aug 10.

PMID:
30097488
3.

Real-Time Vital Mineralization Detection and Quantification during In Vitro Osteoblast Differentiation.

Serguienko A, Wang MY, Myklebost O.

Biol Proced Online. 2018 Aug 1;20:14. doi: 10.1186/s12575-018-0079-4. eCollection 2018.

4.

Patterns of genomic evolution in advanced melanoma.

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE.

Nat Commun. 2018 Jul 10;9(1):2665. doi: 10.1038/s41467-018-05063-1.

5.

Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples.

Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA.

PLoS One. 2018 May 17;13(5):e0197456. doi: 10.1371/journal.pone.0197456. eCollection 2018.

6.

Sample-Index Misassignment Impacts Tumour Exome Sequencing.

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E.

Sci Rep. 2018 Mar 28;8(1):5307. doi: 10.1038/s41598-018-23563-4.

7.

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E.

Int J Mol Sci. 2018 Mar 23;19(4). pii: E969. doi: 10.3390/ijms19040969.

8.

Personal Cancer Genome Reporter: variant interpretation report for precision oncology.

Nakken S, Fournous G, Vodák D, Aasheim LB, Myklebost O, Hovig E.

Bioinformatics. 2018 May 15;34(10):1778-1780. doi: 10.1093/bioinformatics/btx817.

9.

Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b.

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E.

Sci Rep. 2017 Aug 28;7(1):9655. doi: 10.1038/s41598-017-10189-1.

10.

PP2A Regulatory Subunit B55γ is a Gatekeeper of Osteoblast Maturation and Lineage Maintenance.

Serguienko A, Hanes R, Grad I, Wang MY, Myklebost O, Munthe E.

Stem Cells Dev. 2017 Oct 1;26(19):1375-1383. doi: 10.1089/scd.2017.0129. Epub 2017 Aug 10.

PMID:
28805158
11.

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA.

Mol Cancer. 2017 Jul 6;16(1):116. doi: 10.1186/s12943-017-0691-y.

12.

Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.

Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM, Campbell PJ.

Nat Commun. 2017 Jun 23;8:15936. doi: 10.1038/ncomms15936.

13.

Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA.

Genome Med. 2017 May 24;9(1):46. doi: 10.1186/s13073-017-0434-0.

14.

High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA.

Int J Cancer. 2017 Jul 1;141(1):184-190. doi: 10.1002/ijc.30726. Epub 2017 Apr 21.

15.

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.

16.

Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA.

BMC Cancer. 2017 Jan 6;17(1):29. doi: 10.1186/s12885-016-2992-8.

17.

Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene.

Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA.

PLoS One. 2016 Sep 29;11(9):e0163859. doi: 10.1371/journal.pone.0163859. eCollection 2016.

18.

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.

PMID:
27498913
19.

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH.

Cancer Res. 2016 Sep 1;76(17):5092-102. doi: 10.1158/0008-5472.CAN-16-0658. Epub 2016 Aug 3.

20.

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O.

Oncotarget. 2016 Aug 23;7(34):54583-54595. doi: 10.18632/oncotarget.10518.

21.

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report.

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GHS, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS.

Clin Sarcoma Res. 2016 Mar 16;6:3. doi: 10.1186/s13569-016-0043-5. eCollection 2016.

22.

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å.

Front Genet. 2016 May 11;7:85. doi: 10.3389/fgene.2016.00085. eCollection 2016.

23.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2016 May;26(5):717.2. doi: 10.1101/gr.206557.116. No abstract available.

24.

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA.

Oncotarget. 2016 Feb 2;7(5):5273-88. doi: 10.18632/oncotarget.6567.

25.

Genomic landscape of liposarcoma.

Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C, Tyner JW, Ogawa S, Koeffler HP.

Oncotarget. 2015 Dec 15;6(40):42429-44. doi: 10.18632/oncotarget.6464.

26.

Genome sequencing in research requires a new approach to consent.

Budin-Ljøsne I, Bentzen HB, Solbakk JH, Myklebost O.

Tidsskr Nor Laegeforen. 2015 Dec 1;135(22):2031-2. doi: 10.4045/tidsskr.15.0944. eCollection 2015 Dec 1. English, Norwegian. No abstract available.

27.

HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Schneider-Stock R, Ståhlberg A, Åman P.

Oncotarget. 2016 Jan 5;7(1):433-45. doi: 10.18632/oncotarget.6336.

28.

Norwegian Cancer Genomics Consortium: a platform for research on personalized cancer medicine in a public health system.

Myklebost O.

Drug Discov Today. 2015 Dec;20(12):1419-21. doi: 10.1016/j.drudis.2015.10.003. Epub 2015 Oct 28. No abstract available.

PMID:
26520668
29.

Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls.

Myklebost O.

Per Med. 2015 Nov;12(6):593-602. doi: 10.2217/pme.15.20. Epub 2015 Nov 6.

PMID:
29750616
30.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova SG, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2015 Jun;25(6):814-24. doi: 10.1101/gr.190470.115. Epub 2015 May 11. Erratum in: Genome Res. 2016 May;26(5):717.2.

31.

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A.

Blood Cancer J. 2015 Mar 20;5:e299. doi: 10.1038/bcj.2015.24.

32.

Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E.

Oncotarget. 2015 Feb 10;6(4):2451-65.

33.

Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death.

Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK.

Mol Cancer. 2015 Jan 27;14:14. doi: 10.1186/s12943-014-0278-9.

34.

The architecture and evolution of cancer neochromosomes.

Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KH, Damore MA, Deans AJ, Papenfuss AT, Thomas DM.

Cancer Cell. 2014 Nov 10;26(5):653-67. doi: 10.1016/j.ccell.2014.09.010. Epub 2014 Nov 10.

35.

Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines.

Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E.

PLoS One. 2014 Aug 22;9(8):e103873. doi: 10.1371/journal.pone.0103873. eCollection 2014.

36.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, Veer LV, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group.

Science. 2014 Aug 1;345(6196):1251343. doi: 10.1126/science.1251343.

37.

Performance comparison of four exome capture systems for deep sequencing.

Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA.

BMC Genomics. 2014 Jun 9;15:449. doi: 10.1186/1471-2164-15-449.

38.

The regulatory landscape of osteogenic differentiation.

Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza-Zepeda LA.

Stem Cells. 2014 Oct;32(10):2780-93. doi: 10.1002/stem.1759.

39.

Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model.

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA.

Mol Cancer. 2014 Apr 28;13:93. doi: 10.1186/1476-4598-13-93.

40.

Generation and characterization of an immortalized human mesenchymal stromal cell line.

Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O.

Stem Cells Dev. 2014 Oct 1;23(19):2377-89. doi: 10.1089/scd.2013.0599. Epub 2014 Jun 30.

41.

The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.

Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O.

Cancer Med. 2014 Feb;3(1):36-46. doi: 10.1002/cam4.170. Epub 2013 Dec 17.

42.

Epigenetic regulation and functional characterization of microRNA-142 in mesenchymal cells.

Skårn M, Barøy T, Stratford EW, Myklebost O.

PLoS One. 2013 Nov 13;8(11):e79231. doi: 10.1371/journal.pone.0079231. eCollection 2013.

43.

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM.

Nat Genet. 2013 Dec;45(12):1479-82. doi: 10.1038/ng.2814. Epub 2013 Oct 27. Erratum in: Nat Genet. 2014 Mar;46(3):316. Goodie, Victoria [corrected to Goody, Victoria].

44.

Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.

Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI.

Transl Oncol. 2013 Oct 1;6(5):546-53. eCollection 2013.

45.

Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O.

Br J Cancer. 2013 Oct 15;109(8):2228-36. doi: 10.1038/bjc.2013.549. Epub 2013 Sep 24.

46.

Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome.

Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA.

Exp Cell Res. 2013 Aug 15;319(14):2230-43. doi: 10.1016/j.yexcr.2013.06.004. Epub 2013 Jun 18.

47.

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM.

BMC Cancer. 2013 May 20;13:245. doi: 10.1186/1471-2407-13-245.

48.

Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity.

Stratford EW, Bostad M, Castro R, Skarpen E, Berg K, Høgset A, Myklebost O, Selbo PK.

Biochim Biophys Acta. 2013 Aug;1830(8):4235-43. doi: 10.1016/j.bbagen.2013.04.033. Epub 2013 May 2.

PMID:
23643966
49.

Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas.

Bianchini L, Birtwisle L, Saâda E, Bazin A, Long E, Roussel JF, Michiels JF, Forest F, Dani C, Myklebost O, Birtwisle-Peyrottes I, Pedeutour F.

Genes Chromosomes Cancer. 2013 Jun;52(6):580-90. doi: 10.1002/gcc.22055. Epub 2013 Mar 18.

PMID:
23508853
50.

A small molecule approach to engineering vascularized tissue.

Doorn J, Fernandes HA, Le BQ, van de Peppel J, van Leeuwen JP, De Vries MR, Aref Z, Quax PH, Myklebost O, Saris DB, van Blitterswijk CA, de Boer J.

Biomaterials. 2013 Apr;34(12):3053-63. doi: 10.1016/j.biomaterials.2012.12.037. Epub 2013 Jan 29.

PMID:
23369216

Supplemental Content

Loading ...
Support Center